Last reviewed · How we verify
NCT04643665
Prediction of Pulmonary Graft Dysfunction After Double-lung Transplantation (PGD3-AI Study)
trial testing Double-lung transplantation in Transplant Dysfunction in 478 participants. Completed in 5 October 2020.
31 December 2019
Quick facts
| Lead sponsor | Hopital Foch |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 478 |
| Start date | 1 January 2012 |
| Primary completion | 31 December 2019 |
| Estimated completion | 5 October 2020 |
Drugs / interventions tested
- Double-lung transplantation
Conditions studied
- Transplant Dysfunction — all drugs for Transplant Dysfunction →
- Transplantation, Lung — all drugs for Transplantation, Lung →
Sponsor
Hopital Foch — full company profile →
Who can join
12 and older, any sex, with Transplant Dysfunction or Transplantation, Lung. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The thundering evolution of lung transplantation management during the past ten years and primary graft dysfunction (PGD) new definition have led to new predictive factors of PGD. Therefore, we retrospectively analyzed a monocentric database using a machine-learning method, to determine the predictive factors of grade 3 PGD (PGD3), defined as a PaO2/FiO2 ratio \< 200 or being under extracorporeal membrane oxygenation (ECMO) at postoperative day 3. We included all double lung transplantation from 2012 to 2019 and excluded multi-organ transplant, cardiopulmonary bypass, or repeated transplantation during the study period for the same patient. Recipient, donor and intraoperative data were added in a gradient boosting algorithm step-by-step according to standard transplantation stages. Dataset will be split randomly as 80% training set and 20% testing set. Relationship between predictive factors and PGD3 will be represented as ShHapley Additive exPlanation (SHAP) values.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04643665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant Dysfunction
Currently open trials in the same condition.
- NCT06025240 — Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients · recruiting
Other Hopital Foch trials
Trials by the same sponsor.
- NCT06980844 — Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies · NA · not yet recruiting
- NCT06757244 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · Phase 2 · recruiting
- NCT06631794 — Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students · not yet recruiting
- NCT06533436 — Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation · NA · recruiting
- NCT06476002 — Analysis of the Understanding of the French Version of the Vulvar Pain Assessment Questionnaire · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04643665 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hopital Foch
- Last refreshed: 25 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing